Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Bruno Iles, Isabela Ribeiro de Sá Guimarães Nolêto, Flaviane França Dourado, Fábio de Oliveira Silva Ribeiro, Alyne Rodrigues de Araújo, Taiane Maria de Oliveira, Jessica Maria Teles Souza, Ayslan Batista Barros, Gabrielle Costa Sousa, Antônia Carla de Jesus Oliveira, Conceição da Silva Martins, Mariana de Oliveira Viana Veras, Renata Ferreira de Carvalho Leitão, José Roberto de Souza de Almeida Leite, Durcilene Alves da Silva & Jand Venes Rolim Medeiros. (2021) Alendronate sodium-polymeric nanoparticles display low toxicity in gastric mucosal of rats and Ofcol II cells. NanoImpact 24, pages 100355.
Crossref
Crossref
Eri Takusari, Kiyomi Sakata, Tsutomu Hashimoto, Yasumasa Fukushima, Toshitaka Nakamura & Hajime Orimo. (2020) Trends in Hip Fracture Incidence in Japan: Estimates Based on Nationwide Hip Fracture Surveys From 1992 to 2017. JBMR Plus 5:2.
Crossref
Crossref
Usha SalagameErich V. KliewerAlain DemersEmily BanksLouiza S. VelentzisDavid GoldsburySam EggerWilliam D. LeslieKaren Canfell. (2020) Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations. Journal of Women's Health 29:2, pages 177-186.
Crossref
Crossref
Nicole C. Wright, J. Walker Blackston & Kenneth G. Saag. (2019) Changing rates in fracture trends are temporally associated with declining testing and treatment: reality or ecologic fallacy?. Current Opinion in Rheumatology 31:3, pages 316-320.
Crossref
Crossref
J. Tamaki, K. Fujimori, S. Ikehara, K. Kamiya, S. Nakatoh, N. Okimoto, S. Ogawa, S. Ishii & M. Iki. (2019) Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012–2015. Osteoporosis International 30:5, pages 975-983.
Crossref
Crossref
Kimberly E Lind, Mikaela L Jorgensen, Leonard C Gray, Andrew Georgiou & Johanna I Westbrook. (2019) Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities. Health Services Insights 12, pages 117863291985211.
Crossref
Crossref
J. Yoo, J.S. Lee, S. Kim, B.S. Kim, H. Choi, D.Y. Song, W.B. Kim & C.W. Won. (2018) Length of hospital stay after hip fracture surgery and 1-year mortality. Osteoporosis International 30:1, pages 145-153.
Crossref
Crossref
Cristiana Cipriani, Jessica Pepe, Salvatore Minisola & E. Michael Lewiecki. (2018) Adverse effects of media reports on the treatment of osteoporosis. Journal of Endocrinological Investigation 41:12, pages 1359-1364.
Crossref
Crossref
Francisco Javier Aguilar del Rey & Olga Pérez González. (2018) Epidemiología de las fracturas osteoporóticas en Andalucía en el período 2000-2010. Medicina Clínica 150:8, pages 297-302.
Crossref
Crossref
Francisco Javier Aguilar del Rey & Olga Pérez González. (2018) Epidemiology of osteoporotic fractures in Andalusia, Spain, from 2000-2010. Medicina Clínica (English Edition) 150:8, pages 297-302.
Crossref
Crossref
Ott Laius, Heti Pisarev, Katre Maasalu, Sulev Kõks & Aare Märtson. (2017) Trends in and relation between hip fracture incidence and osteoporosis medication utilization and prices in Estonia in 2004–2015. Archives of Osteoporosis 12:1.
Crossref
Crossref
Shinya Tanaka, Akira Yoshida, Shinjiro Kono, Tadanori Oguma, Kyoichi Hasegawa & Manabu Ito. (2016) Effectiveness of elcatonin for alleviating pain and inhibiting bone resorption in patients with osteoporotic vertebral fractures. Journal of Bone and Mineral Metabolism 35:5, pages 544-553.
Crossref
Crossref
Sundeep Khosla, Jane A Cauley, Juliet Compston, Douglas P Kiel, Clifford Rosen, Kenneth G Saag & Elizabeth Shane. (2017) Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. Journal of Bone and Mineral Research 32:3, pages 424-430.
Crossref
Crossref
Kristynn J. Sullivan, Lisa E. Husak, Maria Altebarmakian & W. Timothy Brox. (2016) Demographic factors in hip fracture incidence and mortality rates in California, 2000–2011. Journal of Orthopaedic Surgery and Research 11:1.
Crossref
Crossref
Samuel Hawley, Jose Leal, Antonella Delmestri, Daniel Prieto‐Alhambra, Nigel K Arden, Cyrus Cooper, M Kassim Javaid & Andrew Judge. (2016) Anti‐Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time‐Series Analysis. Journal of Bone and Mineral Research 31:11, pages 2008-2015.
Crossref
Crossref
H. Orimo, Y. Yaegashi, T. Hosoi, Y. Fukushima, T. Onoda, T. Hashimoto & K. Sakata. (2016) Hip fracture incidence in Japan: Estimates of new patients in 2012 and 25-year trends. Osteoporosis International 27:5, pages 1777-1784.
Crossref
Crossref
Smita Jha, Zhong Wang, Nicholas Laucis & Timothy Bhattacharyya. (2015) Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis. Journal of Bone and Mineral Research 30:12, pages 2179-2187.
Crossref
Crossref
C. Klop, D. Gibson-Smith, P. J. M. Elders, P. M. J. Welsing, H. G. M. Leufkens, N. C. Harvey, J. W. J. Bijlsma, T.-P. van Staa & F. de Vries. (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporosis International 26:7, pages 1919-1928.
Crossref
Crossref
Patricia Tanios Haddad, Márcio Salazar & Luzmarina Hernandes. (2015) Histomorphometry of the organic matrix of the femur in ovariectomized rats treated with sodium alendronate. Revista Brasileira de Ortopedia (English Edition) 50:1, pages 100-104.
Crossref
Crossref
Patricia Tanios Haddad, Márcio Salazar & Luzmarina Hernandes. (2015) Histomorfometria da matriz orgânica do fêmur de ratas ovariectomizadas tratadas com alendronato de sódio. Revista Brasileira de Ortopedia 50:1, pages 100-104.
Crossref
Crossref
S. Maria Alves, D. Castiglione, C. Maria Oliveira, B. de Sousa & M. Fátima Pina. (2013) Age–period–cohort effects in the incidence of hip fractures: political and economic events are coincident with changes in risk. Osteoporosis International 25:2, pages 711-720.
Crossref
Crossref
Sam Polesie, Ulf Sigurdsen & Kristian Bjørgul. (2013) Unchanging Incidence of Hip Fracture in Southeastern Norway. Geriatric Orthopaedic Surgery & Rehabilitation 4:2, pages 58-63.
Crossref
Crossref
Sandra Maria Alves, Theodoros Economou, Carla Oliveira, Ana Isabel Ribeiro, Nuno Neves, Enrique Goméz-Barrena & Maria Fátima Pina. (2013) Osteoporotic hip fractures: Bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone 53:2, pages 430-436.
Crossref
Crossref
L. H. Martín Arias, C. Treceño, P. García-Ortega, J. Rodríguez-Paredes, A. Escudero, M. Sáinz, I. Salado, V. Velasco & A. Carvajal. (2012) Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study. European Journal of Clinical Pharmacology 69:3, pages 559-564.
Crossref
Crossref
W. D. Leslie, L. M. Giangregorio, M. Yogendran, M. Azimaee, S. Morin, C. Metge, P. Caetano & L. M. Lix. (2011) A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving. Osteoporosis International 23:5, pages 1623-1629.
Crossref
Crossref
Mickaël Hiligsmann, Olivier Bruyère, Dominique Roberfroid, Cécile Dubois, Yves Parmentier, Joëlle Carton, Johann Detilleux, Pierre Gillet & Jean-Yves Reginster. (2012) Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007). Arthritis Care & Research 64:5, pages 744-750.
Crossref
Crossref
C. Corradini, V. Macchi, E. Malagoli, F. Ferrara, W. Stuflesser, A. Maione & C. Verdoia. (2012) Gestione ortopedica delle fratture da fragilità ossea: attualità e prospettiveOrthopaedic management of fragility fractures: current state and perspectives. Archivio di Ortopedia e Reumatologia 122:3-4, pages 8-9.
Crossref
Crossref